Excellent
Mostly Aligned
Patient Risk:
Low
Summary
AI-generated content is strongly supported by the provided FDA label excerpts for tirzepatide regarding thyroid C-cell tumor risk, the boxed warning, contraindications (MTC/MEN 2), and counseling/monitoring guidance. No direct contradictions or label-critical omissions are identified for the stated claim.
Category Scores
Accurate Statements
Tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas/carcinomas) in rats, and it is unknown whether this translates to humans including MTC.
Supported by 5.1 and Boxed Warning; also consistent with 13.1 for tumor findings.
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Supported by Contraindications (4) and reiterated in the Boxed Warning.
Patients should be counseled about potential risk for MTC and symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Supported by 5.1 and Boxed Warning.
Routine monitoring with serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO.
Supported by 5.1 and reiterated in the Boxed Warning.
Risk of Thyroid C-Cell Tumors is described as a serious adverse reaction in the prescribing information.
Supported by 6 Adverse Reactions (serious adverse reaction list includes 'Risk of Thyroid C-Cell Tumors').
Unsupported Statements
None identified.
All substantive claims made in the provided AI assessment text map to the supplied label excerpts for thyroid C-cell tumors/MTC risk.
Contradictions
Low
AI Statement
None identified.
Label Reference
Important Omissions
None material to evaluating the stated claim. The AI also does not need to restate additional thyroid evaluation steps (e.g., what to do if calcitonin is elevated) unless included in the original AI claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI aligns with label-required contraindication and boxed-warning counseling elements for thyroid C-cell tumor/MTC risk and does not introduce contradictory or unsupported safety assertions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No substantive labeling conflicts found; only minor potential incompleteness versus the full 5.1 workup/threshold details if the original intent was to fully operationalize monitoring/evaluation steps.
Suggested Improvement
If reproducing the label guidance verbatim, include the label’s additional specifics on evaluation when calcitonin is measured and elevated and evaluation of nodules on physical exam or imaging, as described in 5.1.